As part of our ongoing transformation to sharpen our focus, we have decided to explore strategic options for Rebyota. To date, more than five thousand patients suffering from recurrent Clostridioides difficile infection (rCDI) have found new hope when treated with Rebyota. Without commercial critical mass in this therapy area at Ferring, we believe that this first-in-class, innovative product could benefit many more patients with a new approach to its continued commercialisation. As a result, Ferring will reduce commercial efforts in the United States while ensuring uninterrupted access for patients.
Health Technology Insights: Jonathan Blackburn Joins Net Health’s Executive Team as Chief Revenue Officer
Approved by the U.S. Food and Drug Administration (FDA) in 2022, Rebyota was the first FDA-approved faecal microbiota transplant, indicated for the prevention of rCDI in adults following antibiotic treatment for recurrent CDI. This milestone marked a significant advancement in understanding the role of the human microbiome in health and disease.
Health Technology Insights: Noul Supplies AI Diagnostic Platform miLab to Charité Hospital
Ferring remains committed to advancing the science of the human microbiome to address significant unmet medical needs. The company intends to build on the valuable insights gained from the development and commercialisation of Rebyota as it continues its efforts to advance second-generation microbiome therapies (non-donor-based, oral solutions designed to offer greater convenience for both healthcare professionals and patients) across other indications.
Health Technology Insights: Nigeria Launches Initiative for Metastatic Colorectal Cancer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source – businesswire
